C/2026/5941

6.11.2026

Prior notification of a concentration

(Case M.12470 – SUN PHARMA / ORGANON)

(Text with EEA relevance)

(C/2026/5941)

1. On 28 October 2026, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Sun Pharma America, Inc. (United States), controlled by Sun Pharmaceutical Industries Limited (together with its group companies 'Sun Pharma', India),

— Organon & Co. ('Organon', United States).

Sun Pharma will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Organon.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

— Sun Pharma is a specialty generics company listed on the National Stock Exchange of India and BSE Limited. Its portfolio spans across cardiology, psychiatry, neurology, gastroenterology, and dermatology and includes (i) generics and branded generics, (ii) specialty & complex products, (iii) OTC, (iv) antiretrovirals and (v) active pharmaceutical ingredients. Sun Pharma also has an innovative medicines segment. Sun Pharma is present in over 100 countries, with manufacturing facilities across five continents,

— Organon, listed on the New York Stock Exchange, is a global healthcare company primarily focused on women's health and biosimilars, delivering solutions through prescription therapies and medical devices. Organon's portfolio includes over 70 products, focused on three main pillars: women's health (including contraception and fertility), biosimilars (immunology and oncology), and established brands (primarily off-patent originator products in therapeutic areas such as cardiovascular, respiratory and dermatology). Organon is present in 140 countries, with six manufacturing facilities across the globe.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed concentration to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.12470 – SUN PHARMA / ORGANON

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË